A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00130169
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸University Hospital Medical Center - SUNY at Stony Brook, Stony Brook, New York, United States
GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00125398
- Locations
- 🇺🇸
Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00125424
- Locations
- 🇺🇸
Endoscopic Microsurgery Associates, PA, Towson, Maryland, United States
🇺🇸Clinical Research Associates, Huntsville, Alabama, United States
🇺🇸Rockford Gastroenterology Associates Ltd., Rockford, Illinois, United States
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00124527
An Open Label Dose Escalation Study Of E7080
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT00121719
- Locations
- 🇳🇱
Netherlands Cancer Institute- Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇬🇧Gartnavel General Hospital, Glasgow, United Kingdom
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00121680
An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00121732
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸CTRC, San Antonio, Texas, United States
Safety and Efficacy of APD356 in the Treatment of Obesity
- Conditions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00116740
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Safety and Efficacy of APD356 in the Treatment of Obesity
- Conditions
- First Posted Date
- 2005-03-02
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00104507
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States